

PERSONAL INFORMATION

Name and DoB	CASADEI BEATRICE - 03/10/1986
Address	V.LE CARDUCCI 13/4, 40125 BOLOGNA
Phone	+393920717367
E-mail	beatrice.casadei10@unibo.it
Citizenship	Italian

TRAINING, ACADEMIC APPOINTMENTS AND HOSPITAL APPOINTMENTS
--

23/11/2022 - ongoing	<p>Medical Doctor at “Lymphomas and Chronic lymphoproliferative disorders Unit”, directed by Professor Pier Luigi Zinzani, at IRCSS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology “L. & A. Seràgnoli, Bologna, Italy.</p> <p>Competences:</p> <ul style="list-style-type: none"> - Treatment and management of newly diagnosed and relapsed/refractory patients affected by lymphomas and chronic lymphoproliferative disorders with a complete autonomy in the selection and management of antineoplastic therapy, immunotherapy, cell-therapies, and new drugs - Enrollment and treatment of patients within phase I, II or III clinical trials - CAR T-cell therapy: selection and management of more than 100 patients treated with CAR T-cell in the context of phase I/II clinical trials, expanded access program and AIFA approved CAR T-cells products. - Sub-investigator in more than 50 phases I, II and III clinical trials
01/12/2017 – 22/11/2022	<p>Post-doctoral Research fellow at DIMES (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) and at the Institute of Haematology and Medical Oncology “L. & A. Seràgnoli” - Policlinico “Sant’Orsola-Malpighi” – University of Bologna, Bologna.</p> <p>Research areas: lymphoproliferative disorders and in particular new drugs, immunotherapies and cell-therapies (CAR T-cell therapies) for the treatment of lymphomas patients.</p> <p>I participate as a sub-investigator in more than 40 phases I, II and III clinical trials. In particular, in the last years, my clinical research is being turned into the selection and management of relapsed/refractory B-cell lymphoma patients treated with CAR T-cells in the context of phase I/II clinical trials, expanded access program and AIFA approved CAR T-cells products.</p>
27/11/2017 – 22/11/2022	<p>Clinical assistance at the Institute of Haematology and Medical Oncology “L. & A. Seràgnoli” - Policlinico “Sant’Orsola-Malpighi”</p> <p>During my clinical activity I personally deal with the management of patients suffering from lymphoproliferative diseases and who need antineoplastic treatments in outpatient or inpatient setting.</p>
01/11/ 2017 – 19/05/2021	<p>Ph.D. in Oncology, Hematology and Pathology, at DIMES (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), Alma Mater Studiorum – University of Bologna.</p> <p>During my Ph.D. program I developed a project on the role of the gut microbiota in the response to checkpoint inhibitors in patients with relapsed/refractory B-cell lymphomas (Tutor: Prof. Pier Luigi Zinzani).</p>
31/10/2016 – 31/10/2017	<p>Post-doctoral research fellow at “Columbia University College of Physicians & Surgeons Department of Medicine and Experimental Therapeutic – Center for Lymphoid Malignancies”, New York City (NY). Tutor: Owen A’O’ Connor, MD, PhD</p> <p>During this year I learned about preclinical and clinical drugs development with a focus on hypomethylating agents and immune checkpoint inhibitors in peripheral T-cell lymphomas (PTCL).</p>

07/07/2012 – 06/07/2017	<p>Hematology residency and fellowship at the Institute of Haematology and Medical Oncology “L. & A. Seràgnoli” - Policlinico “Sant’Orsola-Malpighi”, Bologna.</p> <p>In July 2017, I graduated (110/110 cum laude) with a thesis entitled “Nuovo approccio immunoterapico nel trattamento del linfoma non Hodgkin B primitivo del mediastino: il ruolo degli inibitori di PD1 nei pazienti ricaduti/refrattari, esperienza dell’Istituto Seragnoli”. (Tutor: Prof. Pier Luigi Zinzani).</p> <p>I spent my residency in the Hematology wards of the hematology department of the University of Bologna with a special focus on autologous stem cell transplantation (2 years) and allogeneic stem cell transplantation (9 months). During my fellowship, I also practiced with out-patients, focusing on lymphoma patients, with increasing responsibility up to complete autonomy about chemotherapy, immunotherapy and invasive hematological procedures. I also conducted as sub investigators, a number of important early phase clinical trials on new drugs in the treatment of relapsed and refractory lymphomas.</p>
July 2011 – June 2012	<p>Scholarship with the project "Terapie Innovative Nei Linfomi" at the Institute of Haematology and Medical Oncology “L. & A. Seràgnoli” - Policlinico “Sant’Orsola-Malpighi”, Bologna.</p>
September 2009 – July 2011	<p>Hematology Internship at the Institute of Haematology and Medical Oncology “L. & A. Seràgnoli” - Policlinico “Sant’Orsola-Malpighi”, Bologna.</p>
October 2005 – July 2011	<p>School of Medicine and Surgery – University of Bologna, Bologna.</p> <p>20 July 2011, degree at the School of Medicine and Surgery – University of Bologna, with a thesis entitled “Approccio chemioimmunoterapico di prima linea nel trattamento del Linfoma Primitivo del Mediastino: esperienza in 98 pazienti” under the mentorship of Prof. Pier Luigi Zinzani.</p> <p>Final examination score: 110/110 with honour.</p>
September 2000 – June 2005	<p>Liceo Classico statale “G. B. Morgagni”, Forlì.</p> <p>High school graduation, June 2005. Final score 100/100</p>

LICENSURE AND BOARD CERTIFICATIONS	
29 March 2023	Completed the cognitive and skills evaluations in accordance with the curriculum of the American Heart Association Advanced Cardiovascular Life Support (ACLS) Program .
20-Mar-2012	Medical Licenses (number: 04731) at Ordine dei Medici-Chirurghi e degli Odontoiatri della provincia di Forlì-Cesena,
March 2012	Medical Board at Alma Mater Studiorum - Università degli studi di Bologna
AWARDS AND HONORS	
OCTOBER 2020	“Ercole Brusamolino” Prize, for lymphoma clinical research, FIL (Italian lymphoma foundation)
RESEARCH ACTIVITY	
	<p>Scientific publications – author and coauthor of 87 peer-reviewed research publications in print or other media.</p> <p>Abstract - author and coauthor of more than 80 abstracts presented at national and international meetings.</p> <p>Books chapter- coauthor of 3 books:</p> <ol style="list-style-type: none"> 1. “Evaluation and Treatment of Lymphoma” – “ Cancer Rehabilitation: Principles and Practice”, Second Edition edited by Michael D Stubblefield, MD, Springer Publishing Company. 2. “Corso di Malattie del Sangue e degli Organi Emolinfopoietici”, edizione 2020, edited by Prof. Sante Tura, Società editrice Esculapio. 3. “Le terapie cellulari CAR-T”, edizione 2021, edited by Laura Orlando e Giuliana Nepoti, Bononia University Press <p>Medical and surgery thesis co-rapporteur</p>

	Clinical trials – I participate as a sub-investigator in more than 50 phases I, II and III clinical trials, in particular in the last years, my clinical research is being turned into the selection and management of relapsed/refractory B-cell lymphoma patients treated with CAR-T cells in the contest of phase I/II clinical trials, expanded access program and AIFA approved CAR-T cells products.
MEETINGS and TRAINING COURSES	
29 October 2010	Chronic Lymphocytic Leukemia: The two sides of the moon, Meldola
15-17 November 2010	Aggressive Lymphomas Workshop, Bologna
16-19 October 2011	43° Congresso SIE (Italian Society of Hematology), Naples
5 November 2011	Sabato Ematologico della Romagna, Faenza
21 September 2012	Changing Haematology Knowledge, Bologna
2-4 February 2012	5° meeting educazionale Post-ASH 2012, Milan
15-16 April 2012	Cellule staminali e trapianto autologo: nuove strategie di mobilitazione, Bergamo
14-17 June 2012	17° European of Hematology Association meeting (EHA), Amsterdam - Netherlands
17-19 September 2012	2009...2012 T-cell lymphomas: work in progress, Bologna
27 October 2012	Sabato Ematologico della Romagna, Faenza
14-16 February 2013	Novità dal Meeting della Società Americana di Ematologia (ASH), Bologna
5-7 March 2013	Definition of new strategies for evaluating the efficacy of novel therapeutic approaches including the definition of response criteria, Progetto FIL- Cantera, Modena
15-16 April 2013	New Drugs in Hematology, Bologna
18-22 June 2013	12-ICML, Lugano – Switzerland
20-23 October 2013	44° Congresso SIE (Italian Society of Hematology), Verona
6-8 February 2014	Novità dal Meeting della Società Americana di Ematologia (ASH), Naples
12-15 June 2014	19° European of Hematology Association (EHA) meeting, Milan
2-4 October 2014	Riunione Nazionale FIL, Fondazione Italiana Linfomi, Rimini
6-9 December 2014	56° meeting of American Society of Hematology (ASH), San Francisco - USA
13 April 2015	Cardiocare in Ematologia, Focus on Linfoma Non Hodgkin, Bologna
27-29 April 2015	2012...2015. T-cell lymphomas: we are illuminating the darkest tunnel, Bologna
17-20 June 2015	13-ICML, Lugano- Switzerland
11-12 September 2015	L'era Brentuximab Vedotin 5 anni dopo, Roma
4-7 October 2015	45° Congresso Nazionale SIE, Firenze
5-7 November 2015	Riunione Nazionale FIL, Fondazione Italiana Linfomi, Rimini
7-10 December 2015	57° meeting of American Society of Hematology (ASH), Orlando - USA
9-11 May 2016	New Drugs in Hematology, Bologna
24 September 2016	Sabato Ematologico della Romagna, Meldola
9-12 December 2017	59° meeting of American Society of Hematology, Atlanta - USA
14 April 2018	Corso Immediate Life Support (ILS), Bologna
7-9 May 2018	2015...2018 T-cell lymphomas: we are close to the finalization, Bologna
15 May 2018	BGB-3111-212 Rome Investigator's Meeting, Roma
15 September 2018	Progetto Ematologia Romagna, Cesena
1-2 October 2018	New Drugs in Hematology, Bologna
13 October 2018	Progetto Ematologia Romagna, Faenza
5 November 2018	Nuovi Orizzonti Terapeutici nel Mondo dei Linfomi, Bologna
11-13 November 2018	Riunione Nazionale FIL, Fondazione Italiana Linfomi, Rimini
14-15 November 2018	Novartis Oncology Region Europe CTL019 Investigator Meeting Creating A Revolution Together (CART), Barcelona-Spain
1-4 December 2018	59° meeting of American Society of Hematology, San Diego - USA
14 December 2018	Expert input forum: Pembrolizumab nella pratica clinica del trattamento dei pazienti affetti da LHclassico, Roma
15-16 February 2019	Novità dal Meeting della Società Americana di Ematologia, Bologna
14-15 March 2019	5th Post Graduate Lymphoma Conference, Rome
30 March 2019	5° corso di formazione ai professionisti: microbiopassport, Bologna

10-11 April 2019	Impact Meeting, Lisbona - Spain
13-14 May 2019	Aggressive Lymphoma Workshop, Bologna
18-22 June 2019	15th ICML, Lugano-Switzerland
24 June 2019	1st Italian Workshop on CAR-T cell Therapy, Milan
02 July 2019	Progetto formazione sul campo- gruppo di lavoro ER confronto tra specialisti..., Bologna
20-23 September 2019	XVIII international working group on CLL, Edimburg – England
7-9 October 2019	47° Congresso Nazionale SIE (Italian Society of Hematology), Roma
8 November 2019	Mantle Cell Lymphoma: Now and Beyond, Roma
7-10 December 2019	61° meeting of American Society of Hematology, Orlando - USA
30 January-1 February 2020	2 nd European CAR-T cell meeting, Sitges - Spain
11-21 June 2020	European Hematology Association annual congress (virtual due to Sars-COV-2 pandemic)
5-8 December 2020	62° meeting of American Society of Hematology (virtual due to Sars-COV-2 pandemic)
4-6 February 2021	3 rd European CAR-T cell meeting (virtual due to Sars-COV-2 pandemic)
18-22 June 2021	16th ICML – Lugano - Switzerland
25-26 October 2021	48° Congresso Nazionale SIE ((Italian Society of Hematology), Milan
11-14 December 2021	63° meeting of American Society of Hematology (virtual due to Sars-COV2 pandemic)
18-20 May 2022	New Drugs in Hematology, Bologna
9-12 June 2022	European Hematology Association annual congress, Vienna - Austria
20-22 June 2022	T-cell base immunotherapies for lymphoid malignancies, Bologna
07-9 September 2022	6th post graduate Lymphoma conference, Rome
26-28 September 2022	49° Congresso Nazionale SIE (Italian Society of Hematology), Rome
22-24 October 2022	12 th International Symposium on Hodgkin Lymphoma, Cologne - Germany
25-26 October 2022	2018..2022 T-cell lymphomas: finally vision and mission, Bologna
14-15 November 2022	Post graduate CLL meeting, Bologna, Italy
10-13 December 2022	64° meeting of American Society of Hematology, New Orleans
09-11 February 2023	EBMT-EHA 5 th CAR T-cell meeting, Rotterdam
16-17 March 2023	Post graduate on DLBCL meeting, Rome, Italy
13-17 June 2023	17 th ICML, Lugano, Switzerland
15-16 September 2023	T-cell and NK-cell based immunotherapies for Lymphoid Malignancies meeting, Milan, Italy
7-9 October 2023	International workshop on CLL, Boston
23-25 October 2023	50° congresso della Società Italiana di Ematologia (SIE); Rome, Italy
SPEAKER ACTIVITY	
16-19/10/2011	43° Congresso SIE (Italian Society of Hematology), Naples, Italy. Poster presentation (Title: Rituximab combined with MACOP-B regimen and radiotherapy in primary mediastinal large B-cell lymphoma: a retrospective study)
20-23/10/2013	44° Congresso Nazionale SIE (Italian Society of Hematology), Verona, Italy. Oral presentation (Title: La raccolta di cellule staminali dopo precedente radioimmunoterapia è fattibile e non pregiudica l'engraftment dopo il trapianto autologo di cellule staminali nel Linfoma Follicolare)
6-9/12/2014	56° meeting of American Society of Hematology (ASH), San Francisco – USA. Poster presentation (title: the treatment of primary mediastinal large b-cell : a two decades monocentric experience on 98 patients)
09-23/11/2015	Speaker at the Stage “Sindromi Linfoproliferative Croniche”, Bologna, Italy.
17/10/2015	Speaker at Sabato Ematologico della Romagna. Faenza, Italy. (Title: Brentuximab Vedotin nel trattamento del Linfoma anaplastico a grandi cellule CD30+ ricaduto/refrattario)
04-07/10/2015	45° Congresso Nazionale SIE (Italian Society of Hematology), Firenze, Italy. Oral presentation (title: Long term outcome a 7 anni: studio di fase 2, FMRx4 seguito dalbritumomab Tiuxetan nei pazienti affetti da Linfoma Follicolare all'esordio).
24/09/2016	Speaker at Sabato Ematologici della Romagna, Meldola, Italy. (Title: Risposta a lungo termine nel Linfoma di Hodgkin Ricaduto/Refrattario).
9-12/12/2017	59° meeting of American Society of Hematology (ASH), Atlanta – USA Poster presentation (Title: the BBV regimen: a phase II study with bendamustine plus brentuximabvedotin in hodgkin lymphoma and CD30+ peripheral t-cell lymphoma in first salvage setting)
07/06/2018	Speaker at the stage “L'innovazione terapeutica nel Linfoma Mantellare, Linfoma di Hodgkin eLinfoma di derivazione T”, Bologna, Italy.

05/11/2018	Speaker at congresso Nuovi Orizzonti Terapeutici nel Mondo dei Linfomi, Bologna, Italy.
11-13/11/2018	Speaker at National meeting by FIL – Fondazione Italiani Linfomi, Rimini, Italy.
7-9/10/2019	47° Congresso Nazionale SIE (Italian Society of Hematology), Rome, Italy. Oral presentation (title: L'utilizzo Degli Inibitori Del Check-Point Cellulare Nel Trattamento Di Pazienti Affetti Da Linfoma Primitivo Del Mediastino Ricaduto/Refrattario: Esperienza Monocentrica Dell'Istituto Seragnoli).
18/10/2019	Speaker at the event "New Era", Milan, Italy.
21/11/2020	Speaker at Progetto Ematologia Romagna. (title: CAR-T, quali sono i pazienti candidabili?). (virtual due to Sars-COV-2 pandemic)
24/05/2021	Speaker at "Care-To care Echo" (virtual due to Sars-COV-2 pandemic)
18-22/06/2021	16th ICML – Lugano, Switzerland. Poster presentations (title: Gut microbiota role in response to checkpoint inhibitor treatment in patients with relapsed/refractory B-cell Hodgkin lymphoma: an interim analysis from MICRO-LINF study + FDG-PET imaging and radiomics in response assessment of lymphoma patients undergoing chimeric antigen receptor T-cell therapy)
09/04 AND 24/09/2021	Speaker at "Car-Tomeet" project area Emilia Romagna, Bologna, Italy
25-26/10/2021	48° Congresso Nazionale SIE (Italian society of Hematology), Milan, Italy. Oral presentation (title: fdg-PET imaging and radiomics in response assessment of lymphoma patients undergoing CAR t-cell therapy) and poster presentation (title: gut microbiota role in the response to checkpoint inhibitor treatment)
30/10 e 1/11/2021	Speaker at Preceptorship on CAR T-cell therapy, Bologna, Italy
07/12/2021	Speaker at Ottimizzazione delle sinergie clinico-patologiche nella gestione delle malattie linfoproliferative a cellule B, Linfoma mantellare. Digital event.
11-14/12/2021	63° meeting of American Society of Hematology (virtual due to Sars-COV2 pandemic). Poster presentation. (Title: gut microbiota role in response to checkpoint inhibitor treatment in patients with relapsed/refractory b-cell hodgkin lymphoma: the micro-linf study)
25/03 and 12/09/2022	Speaker at "Car-Tomeet" project area Emilia Romagna, Bologna, Italy
20-21/09/2022	Speaker at Preceptorship on CAR T-cell therapy, Bologna, Italy. Title: Profilassi e gestione della tossicità post dimissione del paziente sottoposto a CART
26-28/10/2022	49° Congresso Nazionale SIE (Italian society of Hematology), Rome, Italy. Oral presentation (title: CAR T-cell therapy in aggressive lymphomas: the updated real-life experience of "L. e A. Seragnoli" institute of Bologna)
4/11/2022	Speaker at European School of Hematology (ESH); Paris, France. Title presentation: CAR-T therapy in relapsed/refractory DLBCL: real-world data and future directions within cell and gene technologies.
11-12/11/2022	Speaker at Congresso Nazionale FIL, Naples, Italy
2-3-4/02/2023	Speaker at Post New-Orleans Meeting, novità dalla società Americana di ematologia, Milan, Italy. Title presentation: CAR T-cell therapies for indolent B-cell lymphomas
31/03/2023	Speaker at 1 st Symposium on Innovative Therapies in Hematology, Avellino, Italy. Title presentation: CAR T -cell therapies for B-cell non-Hodgkin lymphomas
12/04/2023	Speaker at Hematolympics course, Milan, Italy
14/04/2023	Speaker at CAR-Talking meeting, Bologna, Italy
13-17/06/2023	Speaker at 17 th ICML, Lugano, Switzerland Poster presentation (Title: Interaction Between Gut Microbiome And Immune Checkpoint Inhibitor Treatment In Lymphoma Patients: Final Results Of The Micro-Linf Study).
12-13/09/2023	Speaker at Preceptorship on CAR T-cell therapy, Bologna, Italy. Title presentation: Profilassi e gestione della tossicità post dimissione del paziente sottoposto a CART.
23/09/2023	Speaker at Improving anti CD20 management, ematologi ed infermieri a confronto per ottimizzare la terapia a durata fissa nella leucemia linfatica cronica, Bologna, Italy. Title presentation: Venetoclax + Obinutuzumab, ottimizzare la gestione della terapia per mantenere l'efficacia del trattamento.
27/09/2023	Speaker at MasterY, MASTERclass in Onco-Hematology, Milan, Italy. Title presentation: treatment of relapsed/refractory DLBCL.
2-3/10/2023	Speaker at Stage 2.0 – Linfomi "Under 40", Bologna - Italy
MEMBERSHIP	SIE (Italian society of Hematology) FIL (Fondazione Italiana Linfomi)
ORCID, SCOPUS AND RESEARCHER-ID	ORCID: 0000-0002-4453-6064 SCOPUS: 47960907100

	RESEARCHER ID: DTL-0416-2022.
H-INDEX	14 (SCOPUS)
TOTAL CITATION INDEX	708 (SCOPUS)
PEER-REVIEWED RESEARCH PUBLICATIONS IN PRINT OR OTHER MEDIA 2023-2019	
1	Single-agent rituximab is an effective salvage therapy in pretreated hairy cell leukemia patients. Broccoli A, Argnani L, Nanni L, Stefoni V, Pellegrini C, Casadei B , Gugliotta G, Carella M, Coppola PE, Bagnato G, Zinzani PL. Blood Adv. 2023 Sep 22:bloodadvances.2023010742. doi: 10.1182/bloodadvances.2023010742. Online ahead of print.PMID: 37738174
2	Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Briest F, Noerenberg D, Hennch C, Yoshida K, Hablesreiter R, Nimo J, Sasca D, Kirchner M, Mansouri L, Inoue Y, Wiegand L, Staiger AM, Casadei B , Korkolopoulou P, Weiner J, Lopez-Guillermo A, Warth A, Schneider T, Nagy Á, Klapper W, Hummel M, Kanellis G, Anagnostopoulos I, Mertins P, Bullinger L, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F. Leukemia. 2023 Aug 30. doi: 10.1038/s41375-023-02013-9. Online ahead of print.PMID: 37648814
3	Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection. Pasquini Z, Toschi A, Casadei B , Pellegrini C, D'Abramo A, Vita S, Beccacece A, Bussini L, Chionsini MC, Dentale N, Cantiani A, Lazzarotto T, Bartoletti M, Nicastrì E, Zinzani P, Giannella M, Viale P.Hematol Oncol. 2023 Jul 15. doi: 10.1002/hon.3206. Online ahead of print.PMID: 37452579
4	Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T-cell pathway in patients with diffuse large B-cell lymphoma. Lolli G, Argnani L, Gini G, Casadei B , Pellegrini C, Tani M, Pavone V, Cimminiello M, Bonifazi F, Zinzani PL. Hematol Oncol. 2023 Jul 13. doi: 10.1002/hon.3211. Online ahead of print.PMID: 37442805
5	Endobronchial presentation of Hodgkin's lymphoma responding to pembrolizumab: a case report Gentilini M, Casadei B , Morigi A, Lolli G, Ferrari M, Carella M, Argnani L, Zinzani PL. Chemotherapy. 2023 Jun 13. doi: 10.1159/000527059. Online ahead of print.PMID: 37311417
6	Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival Tumedei MM, Piccinini F, Azzali I, Pirini F, Bravaccini S, De Matteis S, Agostinelli C, Castellani G, Zanoni M, Cortesi M, Vergani B, Leone BE, Righi S, Gazzola A, Casadei B , Gentilini D, Calzari L, Limarzi F, Sabbatini E, Pession A, Tazzari M, Bertuzzi C. Int J Mol Sci. 2023 Jun 8;24(12):9909. doi: 10.3390/ijms24129909.PMID: 37373066
7	CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study Pensato U, Amore G, Muccioli L, Sammali S, Rondelli F, Rinaldi R, D'Angelo R, Nicodemo M, Mondini S, Sambati L, Asioli GM, Rossi S, Santoro R, Cretella L, Ferrari S, Spinardi L, Faccioli L, Fanti S, Paccagnella A, Pierucci E, Casadei B , Pellegrini C, Zinzani PL, Bonafè M, Cortelli P, Bonifazi F, Guarino. M.J Neurol. 2023 May;270(5):2659-2673. doi: 10.1007/s00415-023-11595-4. Epub 2023 Mar 4.PMID: 36869888
8	Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis Pileri A, Clarizio G, Zengarini C, Casadei B , Sabbatini E, Agostinelli C, Zinzani PL. J Eur Acad Dermatol Venereol. 2023 May;37(5):e615-e617. doi: 10.1111/jdv.18831. Epub 2023 Jan 25.
9	PET/CT in Non-Hodgkin Lymphoma: An Update Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, Casadei B , Zinzani PL, Fanti S. Semin Nucl Med. 2023 May;53(3):320-351. doi: 10.1053/j.semnuclmed.2022.11.001. Epub 2022 Dec 14.PMID: 36522191
10	Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing

	<p>autologous transplantation: A case series. Broccoli A, Argnani L, Coppola PE, Gentilini M, Bagnato G, Lolli G, Carella M, Nanni L, Morigi A, Casadei B, Pellegrini C, Stefoni V, Zinzani PL. Tumori. 2022 Apr 20;3008916221090327. doi: 10.1177/03008916221090327. Epub 2022 Apr 20. PMID: 35441544.</p>
11	<p>Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study. Liu C, Cojutti PG, Giannella M, Roberto M, Casadei B, Cristiano G, Papayannidis C, Vianelli N, Zinzani PL, Viale P, Bonifazi F, Pea F. Pharmaceuticals. 2023 Mar 22;15(3):1022. doi: 10.3390/pharmaceutics15031022.PMID: 36986882</p>
12	<p>BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience. Stefoni V, Argnani L, Carella M, Casadei B, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Coppola PE, Zinzani PL. J Cancer Res Clin Oncol. 2022 Mar 3. doi: 10.1007/s00432-022-03955-w. Epub 2022 Mar 3. PMID: 35239000.</p>
13	<p>Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity De Matteis S, Dicaldo M, Casadei B, Storci G, Laprovitera N, Arpinati M, Maffini E, Cortelli P, Guarino M, Vaglio F, Naddeo M, Sinigaglia B, Zazzeroni L, Guadagnuolo S, Tomassini E, Bertuccio SN, Messelodi D, Ferracin M, Bonafè M, Zinzani PL, Bonifazi F. Front Immunol. 2023 Jan 16;13:1058126. doi: 10.3389/fimmu.2022.1058126. eCollection 2022.PMID: 3672697</p>
14	<p>Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient. Lolli G, Ursi M, Dicaldo M, Casadei B, Storci G, Argnani L, Bonifazi F, Zinzani PL. Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622. Epub 2022 Jul 22. PMID: 35866874.</p>
15	<p>NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma. Vegliante MC, Mazzara S, Zaccaria GM, De Summa S, Esposito F, Melle F, Motta G, Sapienza MR, Opinto G, Volpe G, Bucci A, Gargano G, Enjuanes A, Tabanelli V, Fiori S, Minoia C, Clemente F, Negri A, Gulino A, Morello G, Scattoni A, Zito AF, Tommasi S, Agostinelli C, Vitolo U, Chiappella A, Barbui AM, Derenzini E, Zinzani PL, Casadei B, Rivas-Delgado A, López-Guillermo A, Campo E, Moschetta A, Guarini A, Pileri SA, Ciavarella S. Hematol Oncol. 2022 Jul 18. doi: 10.1002/hon.3050. Epub ahead of print. PMID: 35850118.</p>
16	<p>Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy. De Matteis S, Casadei B, Lolli G, Di Cataldo M, et al. Front Immunol. 2022 Oct 6;13:994731. doi: 10.3389/fimmu.2022.994731. PMID: 36275688; PMCID: PMC9584643.</p>
17	<p>Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review. Pensato U, Muccioli L, Zinzani P, D'Angelo R, Pierucci E, Casadei B, Dicaldo M, De Matteis S, Cortelli P, Bonifazi F, Guarino M. J Neurol. 2022 Aug;269(8):4560-4563. doi: 10.1007/s00415-022-11117-8. Epub 2022 Apr 8. Erratum in: J Neurol. 2022 Jun 8;: PMID: 35396601; PMCID: PMC8992404.</p>
18	<p>Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Pagano L, Criscuolo M, Broccoli A, Piciocchi A, Varettoni M, Galli E, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Frustaci A, Spolzino A, Volpetti S, Annibaldi O, Storti S, Stelitano C, Marchesi F, Offidani M, Casadei B, et al. Blood Cancer J. 2022 Jul 19;12(7):109. doi: 10.1038/s41408-022-00702-9. PMID: 35853850; PMCID: PMC9296486.</p>
19	<p>Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. Argnani L, Casadei B, Pelusi C, Lo Preiato V, Pagotto U, Bertoni F, Zinzani PL. Sci Rep. 2022 Feb 2;12(1):1753. doi: 10.1038/s41598-022-05861-0. PMID: 35110658; PMCID: PMC8810842.</p>
20	<p>Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Broccoli A, Terragna C, Nanni L, Martello M, Armuzzi S, Agostinelli C, Morigi A, Casadei B, Pellegrini C, Stefoni V, Sabattini E, Argnani L, Zinzani PL. Hematol Oncol. 2022 Feb;40(1):57-62. doi: 10.1002/hon.2932. Epub 2021 Oct 15. PMID: 34653277; PMCID: PMC9291464.</p>
21	<p>2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS. Paccagnella A, Farolfi A, Casadei B, Garibotto V, Zinzani P, Fanti S. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1090-1091. doi: 10.1007/s00259-021-05562-2. Epub 2021 Sep 22. PMID: 34550427.</p>

22	Frontal predominant encephalopathy with early paligraha as a distinctive signature of CAR T-cell therapy-related neurotoxicity. Pensato U, Amore G, D'Angelo R, Rinaldi R, Nicodemo M, Rondelli F, Mondini S, Santoro R, Sammali S, Farolfi A, Spinardi L, Faccioli L, Casadei B , Dicaldo M, Bonifazi F, Zinzani P, Cortelli P, Stracciari A, Guarino M. <i>J Neurol</i> . 2021 Aug 23;1–7. doi: 10.1007/s00415-021-10766-5. Epub ahead of print. PMID: 34424399; PMCID: PMC8381707.
23	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Follidela Study. Casadei B , Argnani L, Broccoli A, Patti C, Stefani PM, Cuneo A, Margiotta Casaluci G, Visco C, Gini G, Pane F, D'Alò F, Luzi D, Cantonetti M, Pozzi S, Musuraca G, Rosignoli C, Arcari A, Kovalchuk S, Tani M, Tisi MC, Petrini M, Stefoni V, Zinzani PL. <i>Cancers (Basel)</i> . 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654. PMID: 35158922; PMCID: PMC8833724.
24	Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation. Lolli G, Casadei B , Stefoni V, Argnani L, Bonifazi F, Zinzani PL. <i>Chemotherapy</i> . 2022 May 10. doi: 10.1159/000524891. Epub 2022 May 10. PMID: 35537403.
25	Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report. Lolli G, Casadei B , Argnani L, Pileri A, Pellegrini C, Zinzani PL. <i>Acta Haematol</i> . 2022;145(2):207-209. doi: 10.1159/000518815. Epub 2021 Oct 13. PMID: 34818217.
26	Follicular lymphoma: the diminishing role of chemotherapy. Casadei B , Nanni L, Lolli G, Zinzani PL. <i>J Cancer Metastasis Treat</i> 2022;8:21. https://dx.doi.org/10.20517/2394-4722.2022.05
27	A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine. Filippi F, Baraldi C, Zinzani PL, Casadei B , Pileri A. <i>J Eur Acad Dermatol Venereol</i> . 2022 Oct;36(10):e747-e749. doi: 10.1111/jdv.18269. Epub 2022 Jun 7. PMID: 35617206; PMCID: PMC9348115.
28	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, Melle F, Motta G, Calleri A, Fiori S, Corsini C, Casadei B , Mazzara S, Vitolo U, Bertolini F, Zinzani PL, Alcalay M, Pelicci PG, Pileri S, Tarella C, Derenzini E. <i>Leukemia</i> . 2021 Jul 24. doi: 10.1038/s41375-021-01347-6. Epub ahead of print. PMID: 34304248.
29	Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. Broccoli A, Argnani L, Morigi A, Nanni L, Casadei B , Pellegrini C, Stefoni V, Zinzani PL. <i>J Clin Med</i> . 2021 Dec 13;10(24):5845. doi: 10.3390/jcm10245845. PMID: 34945141; PMCID: PMC8706288.
30	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. Ballotta L, Zinzani PL, Pileri S, Bruna R, Tani M, Casadei B , Tabanelli V, Volpetti S, Luminari S, Corradini P, Lucchini E, Tisi MC, Merli M, Re A, Varettoni M, Pesce EA, Zaja F. <i>Front Oncol</i> . 2021 Dec 6;11:789891. doi: 10.3389/fonc.2021.789891. PMID: 34938664; PMCID: PMC8685372.
31	Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases. Coppola PE, Broccoli A, Argnani L, Casadei B , Stefoni V, Bertuzzi C, Sabattini E, Zinzani PL. <i>Leuk Lymphoma</i> . 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961241. Epub ahead of print. PMID: 34348068.
32	Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report. Lolli G, Casadei B , Pellegrini C, Argnani L, Cocito F, Zinzani PL. <i>Tumori</i> . 2021 Jun 24;3008916211027219. doi: 10.1177/03008916211027219. Epub ahead of print. PMID: 34167407.
33	The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience. Broccoli A, Argnani L, Nanni L, Terragna C, Sabattini E, Gabrielli G, Stefoni V, Pellegrini C, Casadei B , Morigi A, Lolli G, Carella M, Coppola PE, Zinzani PL. <i>Am J Hematol</i> . 2021 Oct 1;96(10):1204-1210. doi: 10.1002/ajh.26287. Epub 2021 Jul 23. PMID: 34245477.
34	Real world evidence of CAR T-cell therapies for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas: a monocentric experience. Casadei B , Argnani L, Guadagnuolo S, Pellegrini C, et al. <i>Cancers</i> 2021, 13, 4789.
35	Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas. Bonifazi F, Defrancesco I, Olivieri J, Barbato F, Lopedote P, Dicaldo M, Sessa M, Dan E, Sinigaglia B, Zazzeroni L, Rizzi S, Tassi C, Casadei B , Zinzani PL, Arpinati M. <i>Bone Marrow Transplant</i> . 2021 Sep;56(9):2295-2298. doi: 10.1038/s41409-021-01359-x. Epub 2021 Jun 9. PMID: 34108674.

36	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B et al. <i>Leukemia</i> . 2021 Sep;35(9):2672-2683. doi: 10.1038/s41375-021-01193-6. Epub 2021 Mar 3. PMID: 33658659
37	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. Casadei B , Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Cavo M, Zinzani PL. <i>Ann Hematol</i> . 2021 Sep;100(9):2261-2268. doi: 10.1007/s00277-020-04364-0. Epub 2020 Dec 10. PMID: 33305333; PMCID: PMC8357719.
38	Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B , Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. <i>Mol Cancer Ther</i> . 2021 Aug;20(8):1422-1430. doi: 10.1158/1535-7163.MCT-20-0377. Epub 2021 Jun 9. PMID: 34108263; PMCID: PMC8941846.
39	Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma. Morigi A, Casadei B , Argnani L, Stefoni V, Sergio E, Cavo M, Zinzani PL. <i>Leuk Lymphoma</i> . 2021 Apr;62(4):1007-1009. doi: 10.1080/10428194.2020.1855342. Epub 2020 Dec 4. PMID: 33274685.
40	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). Pileri A, Guglielmo A, Patrizi A, Casadei B , Bertuzzi C, Zinzani PL, Agostinelli C. <i>J Dtsch Dermatol Ges</i> . 2021 Jan;19(1):99-102. doi: 10.1111/ddg.14197. Epub 2020 Jul 27. PMID: 32717101.
41	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: a real-life experience. Casadei B , Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Cavo M, Zinzani PL. <i>Hematol Oncol</i> . 2020 Sep 9. doi: 10.1002/hon.2803. Epub 2020 Sep 30.
42	Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Casadei B , Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Cavo M, Zinzani PL. <i>Cancer Med</i> . 2020 Sep 2. doi: 10.1002/cam4.3262.
43	Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient. Lolli G, Casadei B , Argnani L, Nanni L, Cavo M, Zinzani P.L. <i>Mediterr J Hematol Infect Dis</i> . 2020 Jul 1;12(1):e2020040. doi: 10.4084/MJHID.2020.040.
44	Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Scotto L, Khinhan C, Casadei B , Mangone M, Douglass E, Murty V, Marchi E, Ma H, George C, Montanari F, Califano A, O'Connor O.A. <i>Genes Chromosomes Cancer</i> . 2020 Jul 2. doi: 10.1002/gcc.22884
45	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. Morigi A., Argnani L., Lolli G., Broccoli A., Pellegrini C., Nanni L., Casadei B , Zinzani P. L. <i>Hematol Oncol</i> . 2020 Jun 28. doi: 10.1002/hon.2773.
46	Management of central nervous system relapse in a young patient affected by primary mediastinal B-cell lymphoma: A case report. Marangon M, Casadei B , Broccoli A, Argnani L, Cavo M, Zinzani PL. <i>Clinical case report</i> , Apr 2020; doi: 10.1002/cc3.2706
47	Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Gentilini M, Casadei B , Broccoli A, Argnani L, Cavo M, Zinzani PL. <i>Acta Haematol</i> . 2020 May 11;1-4. doi: 10.1159/000505716
48	Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) —The Zeno Study. Lolli G, Argnani L, Broccoli A, Marangon M, Pellegrini C, Morigi A, Casadei B , Nanni L, Stefoni V, Carella M, Cavo M, Zinzani PL. <i>BR J Hematol</i> , 2020 Jan; doi: 10.1111/bjh.16404
49	Spontaneous remission of follicular lymphoma. Morigi A, Casadei B , Argnani L, Cavo M, Zinzani PL. <i>Hematol Oncol</i> . 2019 Dec. 37(5):626-627. doi: 10.1002/hon.2653

50	<p>PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.</p> <p>Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, Nanni L, Lolli G, Carella M, Argnani L, Cavo M, Zinzani PL. <i>Haematologica</i>. 2019 Nov;104(11):e521-e522. doi: 10.3324/haematol.2019.215962. Epub 2019 Mar 19</p>
51	<p>Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients.</p> <p>Broccoli A, Forti Parri SN, Pellegrini C, Casadei B, Bonfanti B, Bertolaccini L, Agostinelli C, Boaron M, Fanti S, Nanni C, Argnani L, Zinzani PL. <i>Leuk Lymphoma</i>. 2019 Sep;60(9):2247-2254. doi: 10.1080/10428194.2019.1581931. Epub 2019 Mar 1.</p>
52	<p>Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.</p> <p>Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. <i>Oncologist</i>. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr.</p>
53	<p>A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.</p> <p>Nanni L, Morigi A, Casadei B, Broccoli A, Stefoni V, Argnani L, Cavo M, Zinzani PL. <i>Hematol Oncol</i> 2019 Jan 13. Doi: 10.1002/hon.257</p>
54	<p>New therapies and old side effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia.</p> <p>Pileri A, Starace M, Alessandrini A, Casadei B, Zinzani PL, Piraccini BM. <i>BR J Dermatol</i>. 2018 Dec 18. Doi:10.1111/bjd.17533.</p>
55	<p>Dissection of DLBCL Microenvironment Provides Gene Expression-Based Predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iulius V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. <i>Ann Oncol</i>. 2018 Oct 11. doi: 10.1093/annonc/mdy450.</p>
56	<p>Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report. Pellegrini C, Casadei C, Cellini C, Argnani L, Cavo M, Zinzani PL. <i>Case Report J Cancer Sci Ther/Vol.10.6 149(2018) DOI: 10.4172/1948-5956.1000534.</i></p>
57	<p>The Berlin-Frankfurt-Munster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. Marangon M, Tonialini L, Morigi A, Stefoni V, Broccoli A, Pellegrini C, Casadei B, Argnani L, Cavo M, Zinzani PL. <i>Am J Hematol</i>. 2018 Jun 8, doi:10.1002/ajh.25152.</p>
58	<p>Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Broccoli A, Casadei B, Morigi A, Sottotetti F et al; <i>Oncotarget</i>. 2018; 9(34):23443-23450.</p>
59	<p>Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant. Casadei B, Pellegrini C, Tonialini L, Argnani L, Zinzani PL. <i>Hematol Oncol</i>. 2018 Jan 24. doi: 10.1002/hon.2492.</p>
60	<p>Impressive Response to Pixantrone after Allogenic Transplant in a Multiple Relapsed Diffuse Large B cell Lymphoma. Malaspina F, Pellegrini C, Casadei B, Argnani L, Zinzani PL. <i>Acta Haematol</i>. 2017 Apr 21;137(4):191-194. doi: 10.1159/000465511</p>
61	<p>The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. Broccoli A, Casadei B, Stefoni V, Pellegrini C, Quirini F, Tonialini L, Morigi A, Marangon M, Argnani L, Zinzani PL. <i>BMC Cancer</i>. 2017 Apr 17;17(1):276. doi: 10.1186/s12885-017-3269-6.</p>
62	<p>Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice. Argnani L, Broccoli A, Pellegrini C, Casadei B, Zinzani PL. <i>Hematol Oncol</i>. 2016 Nov 10. doi: 10.1002/hon.2371.</p>

63	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. Gandolfi L, Pellegrini C, Casadei B , Stefoni V, Broccoli A, Tonialini L, Morigi A, Argnani L, Zinzani PL. <i>Oncologist</i> . 2016 Dec;21(12): 1436-1441. PMID: 27486201
64	Short-course R-CHOP followed by (90)Y- Ibritumomab tiuxetan previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-years long-term results. Stefoni V, Casadei B , Bottelli C, Gaidano G, Ciochetto C, Cabras MG, Ansuinelli M, Argnani L, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. <i>Blood Cancer J</i> . 2016 May 13;6:e425. doi: 10.1038/bcj.2016.29. PMID: 27176801
65	90-yttrium ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high risk follicular lymphoma: updat long-term results after a median follow-up of 7 years. Casadei B , Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, Broccoli A, Gandolfi L, Quirini F, Tonialini L, Morigi A, Argnani L, Zinzani PL. <i>Cancer Med</i> . 2016 Mar 14. doi: 10.1002/cam4. 684. PMID:26990782
66	High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. Derenzini E, Stefoni V, Pellegrini C, Gandolfi L, Broccoli A, Casadei B , Quirini F, Argnani L, Tonialini L, Zinzani PL. <i>BMC Cancer</i> . 2015 Nov 9;15:879. doi: 10.1186/s12885-015-1903-8.
67	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. Derenzini E, Iacobucci I, Agostinelli C, Imbrogno E, Storlazzi CT, L Abbate A, Casadei B , Ferrari A, Di Rora AG, Martinelli G, Pileri S, Zinzani PL. <i>Exp Hematol Oncol</i> . 2015 Aug 27;4:24. doi: 10.1186/s40164-015-0019-9. eCollection 2015.
68	Vemurafenib mucosal side-effect. Pileri A, Cricca M, Gandolfi L, Misciali C, Casadei B , Zinzani PL, Patrizi A. <i>J Eur Acad Dermatol Venereol</i> . 2015 mar 12. doi: 10.1111/jdv. 13105.
69	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Derenzini E, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B , Brighenti E, Righi S, Fuligni F, Ghelli Luserna di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL. <i>Oncotarget</i> . 2015 Mar 30; 6(9): 6553-69.
70	The role of Rituximab and positron emission tomography in the treatment of primary mediastinal large B cell lymphoma: experience on 74 patients. Zinzani PL, Broccoli A, Casadei B , Stefoni V, Pellegrini C, Gandolfi L, Maglie R, Argnani L, Pileri S, Fanti S. <i>Hematol Oncol</i> . 2015 Dec; 33(4): 145-50. doi: 10.1002/hon.2172. Epub 2014 Sep 25
71	Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non follicular non-Hodgkin's lymphoma: experience on 143 patients. Zinzani PL, Pellegrini C, Broccoli A, Gandolfi L, Stefoni V, Casadei B , Maglie R, Argnani L, Pileri S. <i>Hematol Oncol</i> . 2015 Sep; 33(3): 141- 6. doi:10.1002/hon.2151. Epub 2014 Jul 2.
72	Long term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Pellegrini C, Stefoni V, Casadei B , Maglie R, Argnani L, Zinzani PL. <i>Ann Hematol</i> . 2014 Nov; 93(11): 1853-7. doi: 10.1007/soo277-014-2121-1. Epub 2014 Jun 8.
73	Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. Pellegrini C, Argnani L, Broccoli A, Stefoni V, Derenzini E, Gandolfi L, Casadei B , Maglie R, Pileri S, Zinzani PL. <i>Oncologist</i> . 2014 Jul; 19(7): 746-50. doi: 10.1634/theoncologist.2013-0463. Epub 2014 May 28.
74	Is it really possible to cure hairy cell leukemia patients only with frontline therapy? Zinzani PL, Stefoni V, Broccoli A, Pellegrini C, Gandolfi L, Casadei B , Maglie R, Pileri S, Argnani L. <i>Ann Hematol</i> . 2014 Sep;93(9):1565-9. doi:10.1007/s00277-014-2081-5
75	Sequential therapy with alternating short courses of R-CHOP (rituximab,cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. Derenzini E, Casadei B , Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. <i>Br J Haematol</i> . 2014 Aug;166(4):625-8. doi: 10.1111/bjh.12894. Epub 2014 Apr 18. PubMed PMID: 24750128.
76	An unrecognized disease in routine clinical practice: the Heyde's Syndrome. Casadei B , Grasso V, Cariani G, Barakat B, Pezzilli R. <i>Emergency care journal</i> 2014, 10:649.

77	Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. Derenzini E, Stefoni V, Maglie R, Casadei B , Pellegrini C, Broccoli A, Stefani G, Fanti S, Motta MR, Narducci R, Argnani L, Zinzani PL. <i>Biol Blood Marrow Transplant</i> . 2013 Dec;19(12):1695-701. Doi:10.1016/j.bbmt.2013.09.004. PMID: 24055654.
78	Fludarabine- mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non- Hodgkin's lymphoma: experience on 142 patients. Zinzani PL, Pellegrini C, Broccoli A, Casadei B , Argnani L, Pileri S. <i>Am J Hematol</i> . 2013. Nov;88(11):E273-6. doi: 10.1002/ajh.23540. Epub 2013 Aug 30. PubMed PMID:23843267
79	Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. Broccoli A, Derenzini E, Pellegrini C, Narducci R, Stefani G, Casadei B , Argnani L, Zinzani PL. <i>Clin Lymphoma Myeloma Leuk</i> . 2013 Aug;13(4):493-5. doi: 10.1016/j.clml.2013.03.008. Epub 2013 May 29. PubMed PMID: 23726017
80	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Pastorelli F, Derenzini E, Plasmati R, Pellegrini C, Broccoli A, Casadei B , Argnani L, Salvi F, Pileri S, Zinzani PL. <i>Leuk Lymphoma</i> . 2013 Oct;54(10):2318-21. doi:10.3109/10428194.2013.773997. Epub 2013 Mar 8. PubMed PMID: 23391144
81	Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. Derenzini E, Casadei B , Pellegrini C, Argnani L, Pileri S, Zinzani PL. <i>Clin Lymphoma Myeloma Leuk</i> . 2013 Jun;13(3):258-65. doi: 10.1016/j.clml.2012.10.003. Epub 2012 Dec 14. PubMed. PMID: 23246162
82	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. Zinzani PL, Pellegrini C, Gandolfi L, Casadei B , Derenzini E, Broccoli A, Quirini F, Argnani L, Pileri S, Celli M, Fanti S, Poletti V, Stefoni V, Baccarani M. <i>Hematol Oncol</i> . 2013 Dec;31(4):183-8. doi: 10.1002/hon.2039. Epub 2012 Dec 5. PubMed PMID: 23212941
83	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. Broccoli A, Stanzani M, Bandini G, Bonifazi F, Stefoni V, Pellegrini C, Derenzini E, Gandolfi L, Quirini F, Argnani L, Tschon M, Casadei B , Baccarani M, Zinzani PL. <i>Leuk Lymphoma</i> . 2013 Aug;54(8):1791-3. doi: 10.3109/10428194.2012.749470. Epub 2012 Dec 22. PubMed. PMID: 23153229.
84	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B , Argnani L, Baccarani M. <i>Hematol Oncol</i> . 2013 Dec;31(4):179- 82. doi: 10.1002/hon.2036. Epub 2012 Oct 29. PubMed PMID: 23108928.
85	Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Zinzani PL, Bonifazi F, Pellegrini C, Casadei B , Argnani L, Motta MR, Dan E, Stanzani M, Arpinati M, Bandini G. <i>Clin Lymphoma Myeloma Leuk</i> . 2012 Aug;12(4):287-9. doi: 10.1016/j.clml.2012.05.001. Epub 2012 May 24. PubMed PMID: 22633165.
86	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B , Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A. <i>Ann Oncol</i> . 2012 Mar;23(3):805-7. doi:10.1093/annonc/mdr633. Epub 2012 Jan 27. PubMed PMID: 22287683.
87	The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B , Baccarani M, Lemoli RM. <i>Bone Marrow Transplant</i> . 2011. Mar;46(3):356- 63. doi: 10.1038/bmt.2010.128. Epub 2010 May

OTHER SKILLS.

MOTHER-LANGUAGE	Italiano
OTHER LANGUAGES	English (level C1)
• Listening	Intermediate (C1)
• Writing	Intermediate (C1)
• Speaking	Intermediate (C1)
Drive Licenses	Patente B

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996 e del successivo 196 del 30 giugno 2003.

Bologna, 19/10/2023

Beatrice Casadei

